|
|||||||||||||
|
|
|||||||||||||
|
Case Report |
|||||||||||||
|
|
|||||||||||||
| Volume 2, Number 3, June 2012, pages 145-150 | |||||||||||||
|
|
|||||||||||||
|
Two Cases of Rapidly Growing Papillary Thyroid Carcinoma After Radioactive Iodine Therapy for Graves’ Disease
aDepartment of Endocrinology, Yamashita Thyroid and Parathyroid Clinic, Fukuoka-city, Hakata-ku, Shimogofukumachi 1-8, 812-0034, Japan bDepartment of Surgery, Yamashita Thyroid and Parathyroid Clinic, Fukuoka-city, Hakata-ku, Shimogofukumachi 1-8, 812-0034, Japan cTajiri Thyroid Clinic, Kumamoto-city, Suizenji 2-6-3, 862-0950, Japan
dCorresponding
author:
Seigo Tachibana. Email:
sei.tac.thyroid@gmail.com Manuscript accepted for publication April 6, 2012 Short title: Thyroid Carcinoma doi:10.4021/jem84w
Abstract
We
herein report two cases of papillary thyroid carcinoma (PTC) after
radioactive iodine therapy (RIT) for Graves’ disease (GD). Case 1: A
25-year-old man visited to our clinic. He had undergone RIT for GD
at 23 years old. His thyroid function was severe hypothyroidism
because of poor compliance of taking levothyroxine (LT4), and
thyroid nodule was detected by neck ultrasonography (US). After his
first visit, his compliance of taking LT4 maintained poor, then his
thyroid nodule grew up from 7 mm to 12 mm for 9 months. Fine needle
aspiration biopsy (FNAB) was performed and the result of FNAB
suggested PTC. Therefore, total thyroidectomy was done. Case 2: A
40-year-old woman was referred to our clinic for the treatment of
PTC. She had also undergone RIT for GD at 34 years old. When she was
39 years old, a thyroid nodule was detected by neck US. Her
compliance of taking LT4 was also poor, and the nodule grew up from
11 mm to 19 mm for 12 months. The result of FNAB was suggestive of
PTC. Therefore, total thyroidectomy was done. In both two cases,
thyroid nodular lesion could not be detected by neck US before RIT.
In conclusion, we considered that this rapid growth of PTC in the
irradiated thyroid gland may be induced by TSH stimulation, and that
routine neck US should be continued after RIT for GD, even if there
is no tumor in the thyroid before RIT. Keywords: Radioactive iodine therapy; Papillary thyroid carcinoma; Graves’ disease; Hypothyroidism
Introduction
It is
well known that radioactive iodine therapy (RIT) for Graves’ disease
(GD) is a safe and useful treatment. It is also well known that the
risk of RIT-induced thyroid cancer is not increased significantly [1].
In this paper, we report two cases of papillary thyroid carcinoma (PTC)
which shows rapid growth after RIT for GD. Case Report Case 1 A 25-year-old Japanese man presented at our clinic, because of his removal. Before he visited our clinic, he underwent RIT (administered 131-I dose: 223 Gy) for GD at 23 years old at T thyroid clinic.
He became hypothyroidism soon after 131-I therapy,
and had to take levothyroxine (LT4).
However, his compliance of taking LT4 was
poor. When he visited our clinic, he discontinued to take
LT4. His thyroid function was as follows; TSH
> 100
μIU/mL,
free thyroxine (FT4) 0.97 ng/dL,
and TSH receptor antibody (TRAb) (1st-generation assays) 51.2%.
Despite severe hypothyroidism, his clinical manifestations were
almost all normal and his other
laboratory examinations
also showed within normal limit. Neck ultrasonography (US) detected
atrophic thyroid and a low echoic mass in
the left lobe. The diameter of the nodule was 7 mm (Fig.1A).
The result of
fine needle aspiration biopsy (FNAB) from
the nodule was indeterminate,
but we did follow-up by neck US,
because the size of the nodule was small and he did not hope
for an operation. After 9 months,
the size of the nodule became 12 mm, then, FNAB
was performed again (Fig.
1A). The result of FNAB indicated PTC (Fig.
2A).
Total thyroidectomy and lymph node dissection of central compartment
was performed. The histological diagnosis was compatible with PTC (Fig.
2B).
Figure
3
shows his thyroid function during the follow-up period after RIT,
and his thyroid function maintained hypothyroidism because of his
poor compliance of taking LT4.
We could not detect
nodular lesion (Fig.
4A)
by US which was done at T thyroid clinic before RIT.
A
40-year-old Japanese woman was referred to our clinic for the
surgery of PTC. She also underwent RIT for GD at 34 years old at
T thyroid clinic. Administered
131-I dose was 183 Gy and her hyperthyroidism had been cured after
RIT. She had to take LT4 because of hypothyroidism, but her
compliance of taking LT4 was also poor.
Her serum TSH
level was often over normal range
as shown in
Figure
5
after RIT. When she was 39 years
old, a low echoic mass was detected in
the right atrophic thyroid
lobe by neck US and the size of the nodule was 11 mm. After
12 months, the size of the nodule was increased up to 19 mm (Fig.
1B) and swollen lymph nodes were also detected in
the central compartment. FNAB from
the tumor indicated suggestive of
PTC. Then, she was referred to our clinic. When she visited
our clinic, her clinical manifestations were almost all normal and
her laboratory data were also
within normal limit. Her thyroid function was as follows; TSH 4.67
μIU/mL,
FT4 1.25 ng/dL, TRAb
(3rd-generation assays) 5.0 IU/L,
thyroglobulin (Tg)
< 0.1ng/mL,
and antithyroglobulin antibody (TgAb) 463 IU/mL.
Neck US showed a low echoic and irregular shaped mass, and FNAB at
our clinic indicated PTC (Fig. 6A).
Therefore, total thyroidectomy and lymph node dissection of central
compartment was performed. The histological diagnosis was compatible
with PTC (Fig. 6B). We also
reviewed neck US
done at T thyroid clinic
before RIT, but we could not detect nodular lesion (Fig.
4B).
In this paper, we reported two cases of PTC after RIT for GD. In general, it is believed that the risk of thyroid cancer is not increased significantly. Ron E et al reported that among adult patients in the Cooperative Thyrotoxicosis Therapy Follow-up Study cohort treated with RIT for GD, a small increase of thyroid cancer mortality was observed. However, this is believed to reflect the nature of the underlying thyroid disease rather than being a consequence of RIT [1]. On the other hand, the increased risk of thyroid cancer after thyroid irradiation in childhood has been recognized [2]. Rivkees SA reported that if relatively high dose of 131-I was administered, the risk of thyroid cancer did not increased because of minimizing the persistence of residual thyroid tissue [3]. In fact, reported four cases of thyroid cancer in children after RIT were all treated with low doses of 131-I [4-9], and high dose of 131-I for children’s and adolescent’s GD would decrease the risks of RIT-induced thyroid tumors [10]. These tendencies were observed not only in children and adolescents, but also in adults. Data from the Cooperative Thyrotoxicosis Therapy Follow-up Study suggested that the amount of residual thyroid tissue after RIT for GD plays an important role in determining the long-term risks of thyroid cancer in adults [11]. In this point of view, we considered that PTC of our two cases was not RIT-induced thyroid cancer, and was already existed micro cancer before RIT, because adequate high dose of 131-I was administered. It is difficult to detect thyroid micro cancers with GD, because the echogenicity of the thyroid of patients with GD is often heterogeneous. The heterogeneous echogenicity of the thyroid of our two patients shown by US made it difficult to detect micro PTC which was considered to be present before RIT. There are many reports of PTC with GD, and the prognosis of PTC with GD is still controversial [12, 13]. Belfiore et al reported that TSH stimulation by TRAb may play a role in determining the high aggressiveness of thyroid cancer in GD patients [12]. On the other hand, some reports of Japanese populations suggested that PTC with GD in Japanese showed nonaggressive clinical features and good prognosis [13, 14]. Our cases showed relatively rapid growth of the size of PTC. There may be two explanations for the rapid growth. Firstly, in both cases, TSH was maintained in high range during the period before surgery, because of poor compliance of taking LT4. Zofan et al reported the possibility that there exists an increment in tumor size as a function of increment in the TSH level [15]. In addition, in both cases, TRAb was also detected to a certain extent (Fig. 3, 5). We considered that TSH stimulation to micro PTC due to serum TSH and TRAb might contribute to relatively rapid growth. Secondly, after RIT, it was considered that normal thyroid follicles became atrophic, but cancer cells persisted in the thyroid gland. The blood perfusion of PTC after RIT would increase disproportionately more than that before RIT, because the thyroid volume was decreased by RIT and the size of PTC was not affected by RIT. Therefore, we suggested that this disproportionately increased blood perfusion to PTC due to TSH stimulation influenced this relatively rapid growth of PTC. On the other hand, there are some reports of anaplastic thyroid carcinoma after RIT [16-18]. In these cases, RIT was performed for PTC, not for GD. Therefore, it was difficult to reflect these cases to our cases directly. However, in these cases, it was reported that RIT to the differentiated thyroid tumor plays a role in the transformation to an undifferentiated tumor due to p53 gene mutation. When the etiology of our cases was considered, this influence of RIT to preexisting PTC should be discussed. We could not detect undifferentiated or poorly differentiated component in the histology, suggesting that there was no dedifferentiation of preexisting PTC due to RIT in our cases.
We
report two cases of rapid growing PTC after RIT for GD and discussed
the pathophysiology. Although such occurrence is rare, routine neck
US should be continued after RIT for GD, even if there is no tumor
in the thyroid before RIT, because the heterogeneous echogenicity of
thyroid due to GD makes it difficult to detect preexisting PTC.
Further, PTC without poorly differentiated component may grow
rapidly as shown in this report. |
|||||||||||||
|
|
|||||||||||||
| References | |||||||||||||
| 1. |
Ron E,
Doody MM, Becker DV, Brill AB, Curtis RE, Goldman MB, Harris BS, 3rd, et
al. Cancer mortality following treatment for adult hyperthyroidism.
Cooperative Thyrotoxicosis Therapy Follow-up Study Group. JAMA.
1998;280(4):347-355. [Medline] [CrossRef] |
| 2. |
Duffy BJ,
Jr., Fitzgerald PJ. Cancer of the thyroid in children: a report of 28
cases. J Clin Endocrinol Metab. 1950;10(10):1296-1308. [Medline] [CrossRef] |
| 3. |
Rivkees
SA. The use of radioactive iodine in the management of hyperthyroidism
in children. Curr Drug Targets Immune Endocr Metabol Disord.
2001;1(3):255-264. [Medline] [CrossRef] |
| 4. |
Kogut MD,
Kaplan SA, Collipp PJ, Tiamsic T, Boyle D. Treatment of Hyperthyroidism
in Children. Analysis of Forty-Five Patients. N Engl J Med.
1965;272:217-221. [Medline] |
| 5. |
Sheline
GE, Lindsay S, Mc CK, Galante M. Thyroid nodules occurring late after
treatment of thyrotoxicosis with radioiodine. J Clin Endocrinol Metab.
1962;22:8-18. [Medline] |
| 6. |
Farbota
LM, Calandra DB, Lawrence AM, Paloyan E. Thyroid carcinoma in Graves'
disease. Surgery. 1985;98(6):1148-1153. [Medline] |
| 7. |
Karlan
MS, Pollock WF, Snyder WH, Jr. Carcinoma of the Thyroid Following
Treatment of Hyperthyroidism with Radioactive Iodine. Calif Med.
1964;101:196-199. [Medline] |
| 8. |
Shore RE.
Issues and epidemiological evidence regarding radiation-induced thyroid
cancer. Radiat Res. 1992;131(1):98-111. [Medline] [CrossRef] |
| 9. |
Gorman
CA, Robertson JS. Radiation dose in the selection of 131I or surgical
treatment for toxic thyroid adenoma. Ann Intern Med. 1978;89(1):85-90.
[Medline] |
| 10. |
Rivkees
SA, Sklar C, Freemark M. Clinical review 99: The management of Graves'
disease in children, with special emphasis on radioiodine treatment. J
Clin Endocrinol Metab. 1998;83(11):3767-3776. [Medline] [CrossRef] |
| 11. |
Dobyns
BM, Sheline GE, Workman JB, Tompkins EA, McConahey WM, Becker DV.
Malignant and benign neoplasms of the thyroid in patients treated for
hyperthyroidism: a report of the cooperative thyrotoxicosis therapy
follow-up study. J Clin Endocrinol Metab. 1974;38(6):976-998. [Medline] [CrossRef] |
| 12. |
Belfiore
A, Garofalo MR, Giuffrida D, Runello F, Filetti S, Fiumara A, Ippolito
O, et al. Increased aggressiveness of thyroid cancer in patients with
Graves' disease. J Clin Endocrinol Metab. 1990;70(4):830-835. [Medline] [CrossRef] |
| 13. |
Yano Y,
Shibuya H, Kitagawa W, Nagahama M, Sugino K, Ito K. Recent outcome of
Graves' disease patients with papillary thyroid cancer. Eur J Endocrinol.
2007;157(3):325-329. [Medline] [CrossRef] |
| 14. |
Kikuchi
S, Noguchi S, Yamashita H, Uchino S, Kawamoto H. Prognosis of small
thyroid cancer in patients with Graves' disease. Br J Surg.
2006;93(4):434-439. [Medline] [CrossRef] |
| 15. |
Zafon C,
Obiols G, Baena JA, Castellvi J, Dalama B, Mesa J. Preoperative
thyrotropin serum concentrations gradually increase from benign thyroid
nodules to papillary thyroid microcarcinomas then to papillary thyroid
cancers of larger size. J Thyroid Res. 2012;2012:530721. [Medline] |
| 16. |
Maatouk
J, Barklow TA, Zakaria W, Al-Abbadi MA. Anaplastic thyroid carcinoma
arising in long-standing multinodular goiter following radioactive
iodine therapy: report of a case diagnosed by fine needle aspiration.
Acta Cytol. 2009;53(5):581-583. [Medline] [CrossRef] |
| 17. |
Kapp DS,
LiVolsi VA, Sanders MM. Anaplastic carcinoma following
well-differentiated thyroid cancer: etiological considerations. Yale J
Biol Med. 1982;55(5-6):521-528. [Medline] |
| 18. |
Shingu K,
Kobayashi S, Yokoyama S, Fujimori M, Asanuma K, Ito KI, Hama Y, et al.
The likely transformation of papillary thyroid carcinoma into anaplastic
carcinoma during postoperative radioactive iodine-131 therapy: report of
a case. Surg Today. 2000;30(10):910-913. [Medline] [CrossRef] |
This is an open-access article distributed
under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly cited.
Digital Object Identifier (DOI):10.4021/jem84w
About
DOI and
CrossRef
Journal of Endocrinology and Metabolism is a member of CrossRef.



